RecruitingNot Applicable

µQFR for Branch Stenosis After Single Stent in Bifurcation Lesions

China290 participantsStarted 2025-08-13

Plain-language summary

Murray-law based single-view quantitative flow ratio (µQFR) has been recommended for guiding percutaneous coronary intervention (PCI) in selective patients. However, it's reliability has not been validated in bifurcation lesions which present complex anatomy and flluid conditions before and after PCI. The goal of this study is to investigate the diagnostic performance of µQFR in side branch after single-stent treatment for bifurcation lesions in patient with obstructive coronary artery diseases.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥ 18 years and provision of written informed consent for biospecimen donation upon hospital admission.
✓. Clinical suspicion or diagnosis of CAD requiring coronary angiography and physiological assessment.
✓. Angiographically confirmed true bifurcation lesions, including but not limited to: left main-left anterior descending-left circumflex (LM-LAD-LCx), left anterior descending-diagonal (LAD-Dg), left circumflex-obtuse marginal (LCx-OM), and right coronary artery-posterior left ventricular-posterior descending artery (RCA-PLV-PDA).
✓. Bifurcation lesion vessel diameter ≥ 2.5 mm with visually estimated angiographic diameter stenosis ≥ 50%.

Exclusion criteria

✕. Acute myocardial infarction.
✕. Cardiogenic shock or severe heart failure (Killip class IV).
✕. Serum creatinine \> 150 μmol/L or estimated glomerular filtration rate (eGFR) \< 45 mL/min/1.73 m² calculated using the CKD-EPI formula.
✕. Known allergy to iodinated contrast media.
✕. History of coronary artery bypass graft surgery.

What they're measuring

Diagnostic accuracy of µQFR in side branch

Timeframe: Perioperative

Trial details

NCT IDNCT07116083

SponsorShanghai Zhongshan Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-08-30

Contact for this trial

Chenguang Li, MD, PhD

008664041990 li.chenguang@zs-hospital.sh.cn

View on ClinicalTrials.gov More Coronary Artery Disease trials